NGS is the most transformative technology in the history of clinical diagnostics — enabling simultaneous analysis of thousands of genes from a single patient sample, detecting mutations that single-gene tests miss, and unlocking precision medicine at scale. The clinical NGS market is growing at a 14.5% CAGR — the fastest in IVD — driven by oncology, rare disease, infectious disease, and prenatal testing. Illumina dominates the sequencing instrument market but faces emerging competition from Oxford Nanopore and PacBio in long-read sequencing. Roche, Thermo Fisher, and QIAGEN supply the reagent kits, bioinformatics pipelines, and clinical workflows that make NGS routine. The regulatory path from research to clinical use — FDA 510(k), PMA, and the EU IVDR Class D classification — is still a barrier for many applications but is progressively being cleared as clinical validation evidence accumulates.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.


Topics Covered
• NGS in Diagnostics Market Size and Forecast 2025-2030 by Application and Region
• Oncology NGS — Tumor Profiling, Companion Diagnostics, and Liquid Biopsy
• Rare Disease and Genetic Testing — Whole Genome Sequencing and Exome Analysis
• Infectious Disease NGS — Pathogen Identification, AMR Detection, and Outbreak Surveillance
• Prenatal and Reproductive NGS — NIPT, PGT, and Carrier Screening
• Sequencing Platforms — Short-Read, Long-Read, and Nanopore Technologies
• Bioinformatics and Clinical Interpretation — Software, AI, and Data Management
• Regulatory Pathway — FDA, EU IVDR, and Global Approval Strategy for NGS Tests
• Competitive Landscape — Illumina, Roche, Thermo Fisher, QIAGEN, Oxford Nanopore
• Investment and Partnership Opportunities — Platform Access, Reagent Supply, and Data Partnerships